Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava

Hepatology Research

Volumn 42, Issue 5, 2012, Pages 442-453

  Murakami, Eisuke ^a   Aikata, Hiroshi ^a   Miyaki, Daisuke ^a   Nagaoki, Yuko ^a   Katamura, Yoshio ^a   Kawaoka, Tomokazu ^a   Takaki, Shintaro ^a   Hiramatsu, Akira ^a   Waki, Koji ^a   Takahashi, Shoichi ^a   Kimura, Tomoki ^b   Kenjo, Masahiro ^b   Nagata, Yasushi ^b   Ishikawa, Masaki ^b   Kakizawa, Hideaki ^b   Awai, Kazuo ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Hepatocellular carcinoma; Interferon; Radiotherapy; Venous tumor thrombosis

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; HEPATITIS C ANTIBODY; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; DISEASE ASSOCIATION; FEMALE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC VEIN TRUNK TUMOR THROMBOSIS; HUMAN; INFERIOR VENA CAVA TUMOR THROMBOSIS; LIVER CELL CARCINOMA; MALE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS PREVENTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR THROMBUS; VEIN THROMBOSIS;

EID: 84861306027     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00943.x     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
3. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41: 100-6.
4. Kamada K, Kitamoto M, Aikata H et al. Combination of transcatheter arterial chemoembolization using cisplatinlipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-90.
5. Kawaoka T, Aikata H, Takaki S et al. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 32: 687-94.
6. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167: 759-68.
7. Seong J, Keum KC, Han KH et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 393-7.
8. Iwamiya T, Sawada S, Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994; 33 (Suppl): S134-8.
9. Uka K, Aikata H, Takaki S et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42: 845-53.
10. Uka K, Aikata H, Takaki S et al. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27: 1209-16.
11. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
12. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-64.
13. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
14. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
15. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004.
16. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-87.
17. Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
18. Uka K, Aikata H, Takaki S et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-20.
19. Fujii T, Takayasu K, Muramatsu Y et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23: 105-9.
20. Kim DY, Park W, Lim DH et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-26.
21. Toya R, Murakami R, Baba Y et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007; 84: 266-71.
22. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-8.
23. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
24. Langer CJ, Curran WJ, Keller SM et al. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am 1996; 2: 99-105.
25. Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996; 35: 343-50.
26. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
27. Katamura Y, Aikata H, Takaki S et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without threedimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009; 44: 492-502.
28. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
29. Lawrence TS, Dworzanin LM, Walker-Andrews SC et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 1991; 20: 555-61.
30. Ohishi W, Kitamoto M, Aikata H et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003; 38: 894-900.
31. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127 (5 Suppl 1): S17-26.
32. Falasca K, Ucciferri C, Dalessandro M et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006; 36: 144-50.
33. Uka K, Aikata H, Mori N et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008; 75: 8-16.
34. Nakamura M, Nagano H, Marubashi S et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112: 1765-71.
35. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
36. Cheng AL, Kong YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.